NetraMark expands its clinical trial product suite
NetraMark Holdings Inc. is broadening its clinical trial solutions to meet what sponsors are asking for right now. By weaving advanced generative AI into its tools, the company aims to lift trial success rates, sharpen market access strategies, and help teams clearly differentiate their products where it matters most—at the bedside and in the marketplace.
Client-driven, built on NetraAI
CEO George Achilleos announced the expansion as a direct response to ongoing client requests. The message is simple: keep pushing the limits of what’s possible in clinical trials with modern machine learning. At the core is NetraAI, the company’s platform designed to analyze clinical trial data and turn it into practical, decision-ready insights for sponsors and their partners.
New capabilities at a glance
NetraMark’s suite now features five focused offerings, each aimed at a common point of friction in clinical development. Together, they support smarter design, clearer interpretation, and faster movement from data to action.
1. Protocol Enrichment
NetraMark’s core Protocol Enrichment capability surfaces distinct patient personas and the variables that shape how people respond to treatment. Those insights help sponsors make better calls about who to include, how to enrich study populations, and where to focus during development. The result: a higher likelihood of success in the phases that follow.
2. Comprehensive Covariate Analysis
Trials turn on more than primary endpoints. This offering digs into the non-primary variables that can shift results—baseline factors, patterns in response, and signals that might otherwise hide in plain sight. By pinpointing treatment-responsive subpopulations while keeping potential confounders in check, teams get a clearer picture of efficacy and risk.
3. Target Product Profile (TPP) enhancement
The TPP is the north star for a program. It keeps the team aligned on what the therapy should deliver and for whom. NetraMark supports ongoing refinement of the TPP so drug attributes stay in step with clinical needs, regulatory expectations, and market realities—without losing sight of patient benefit.
4. Rapid Market Access
Getting a therapy to the right patients requires more than approval. NetraMark helps clients shape strategies that show how their product stands out in today’s landscape, with evidence grounded in data-driven responder personas. That clarity supports meaningful differentiation and smoother paths to coverage and adoption.
5. Precision Medicine initiatives
Every patient is different. NetraMark’s technology helps identify the variables that drive individual responses, supporting tailored treatment choices and more efficient trials. By aligning therapy characteristics with patient-specific factors, sponsors can raise the odds of positive outcomes while streamlining development.
Broader access, deeper insight
These expanded offerings are available to all clients, underscoring NetraMark’s commitment to support the full drug development lifecycle—from study design to market planning. President Josh Spiegel shared his enthusiasm for delivering solutions that help teams work faster and smarter, pairing cutting-edge analytics with everyday usability to lift efficiency and productivity across programs.
About NetraMark
NetraMark builds generative AI and machine learning solutions for the pharmaceutical industry. Using novel algorithms, the company segments patient datasets into meaningful groups, making complex analyses more tractable and actionable. That focus on explainable, data-driven insight is designed to improve decision-making and, ultimately, raise the ceiling on clinical trial success.
Frequently Asked Questions
Who stands to benefit most from these offerings?
Pharmaceutical and biotechnology companies seeking to improve clinical trial outcomes, shape clearer market access strategies, and differentiate their therapies can benefit directly from NetraMark’s solutions.
What does the Protocol Enrichment capability actually do?
It identifies patient personas and the variables tied to treatment response, helping sponsors choose and enrich study populations so they can make more confident, evidence-based design decisions.
Why is the Target Product Profile (TPP) so important?
The TPP defines the desired characteristics of a therapy and keeps teams aligned throughout development. It acts as a practical guide to ensure the program meets clinical needs and navigates regulatory and market expectations.
How is generative AI used within NetraMark’s products?
NetraMark uses generative AI to analyze clinical trial data, reveal patterns, and surface insights that inform study design, patient selection, and downstream strategy—reducing guesswork and accelerating decisions.
What’s the aim of Precision Medicine in this context?
The goal is to tailor treatment to individual patient characteristics, improving the likelihood of a positive therapeutic response while making trials more efficient and focused.
